An advertised figure in this category names one line of a multi-line bill. On the pricing terms published at ro.co on 24 July 2026, membership and medication are stated as two separate charges. Membership runs $39 for a first month and $74 to $149 thereafter by plan length. Medication is priced separately, by dose, with its own promotions.
Identify the line before arguing about the number
Three people quoting three different costs can all be reading the same published page correctly. One is quoting the introductory access fee, one is quoting ongoing access at a prepaid rate, and one is quoting a maintenance dose of an injectable. Any figure attached to this market needs three qualifiers before it carries meaning: which line, which month, and which strength.
A short advertisement has room for one number. That number is nearly always the smallest one on the page, which is nearly always the introductory access fee. That is not a deception so much as a format limit, and it is exactly why the pricing page rather than the spot is the document to read.
Naming the line is easier with more than one provider in view. Ro, Hims and Hers, and Henry Meds all advertise a small entry figure that sits in front of a larger recurring bill, and a manufacturer channel such as NovoCare quotes the drug alone. A provider like HealthRX sets out its own membership tiers and cash prices for GLP-1 medications, and laying these offers side by side makes it plain that a headline number is a line item rather than a total.
The dose ladder is the price ladder
Every approved agent in this class starts low and climbs, because approved labeling sets out a titration schedule intended to limit gastrointestinal effects. Published cash prices climb with it. Ro’s per-dose tables, retrieved on 24 July 2026, show entry strengths priced far below maintenance strengths on each product, and the gap is large enough to change a household budget rather than round it.
The clinical literature explains why the top of the ladder is where treatment usually lands. Semaglutide’s obesity program studied 2.4 mg weekly, tirzepatide reached 10 mg and 15 mg weekly in its obesity trial, and the tirzepatide sleep apnea program in adults with obesity likewise treated at maintenance strength. These were separate trials in separate populations and are not a head-to-head result, but none of them describes a starting dose held indefinitely.
| Product | Published entry price | Published price at higher strengths | Qualifier attached to the promotion |
|---|---|---|---|
| Wegovy pill, daily semaglutide tablet | $149 a month at 1.5 mg | $299 at 9 mg and 25 mg | Reduced 4 mg price valid for that strength only, sign up by 31 August 2026 |
| Foundayo pill, daily orforglipron | $149 a month at 0.8 mg | $299 at 5.5 mg and above | Manufacturer offer applies at 14.5 mg and higher |
| Wegovy pen, weekly semaglutide | $199 a month at 0.25 mg | $349 from 1 mg to 2.4 mg, $399 at 7.2 mg | Reduced price covers the first two months at 0.25 mg and 0.5 mg, sign up by 31 December 2026 |
| Zepbound KwikPen, weekly tirzepatide | $299 a month at 2.5 mg | $399 at 5 mg, $449 at 7.5 mg and above | Manufacturer offer applies at 7.5 mg and higher |
| Ro Body membership | $39 for the first month | $74 to $149 a month thereafter | The $74 rate requires prepaying twelve months |
Deadlines and strength limits are the fine print that matters
Two qualifiers recur across the promotional lines above, and both are stated openly. A promotion carries a date by which a patient must sign up, and it applies to named strengths rather than to the product. Read together, they describe a discount on the beginning of treatment rather than on treatment.
That has a practical consequence for anyone planning. If a reduced price covers the first two months at the two lowest strengths, and titration moves upward each month by design, the reduced price expires roughly when the regimen becomes the one that trials studied. The published prices are honest about this. Advertising simply has no room to say it.
Cash prices are manufacturer prices, so the competition is on the other line
Ro’s pricing page states that its cash medication prices are the same as those offered through LillyDirect, NovoCare, and TrumpRx, the self-pay channels associated with the manufacturers. If a platform’s drug prices match the manufacturer channel, then the drug line is not where telehealth brands differ. They differ on the access fee, on what that fee includes, on whether an insurance route is pursued first, and on whether the product is a brand or a compounded preparation at all.
That last split is the widest one. A cash-pay compounded provider such as FormBlends typically quotes a single monthly figure covering physician supervision and medication together, which makes the arithmetic simpler at every strength but changes what is being bought, because compounded preparations are not FDA-approved and the agency has published its concerns about unapproved GLP-1 drugs sold for weight loss.
Labs and shipping are usually the smallest variables
Ro describes laboratory testing as included within the membership where a clinician orders it, and states that the cost of medication is not included in the membership fee. An insurance check is offered at no charge. Cash-pay medication is described as shipping to a home address, while a prescription covered by insurance is collected at a retail pharmacy and paid for there at the plan copay.
People shopping an offer tend to ask about shipping and labs first because those are the familiar consumer questions. In this category they are rarely what moves the total. Dose tier and plan length move it, by hundreds of dollars a month rather than tens.
What the advertised number becomes by month four
Take the smallest published combination and walk it forward. Month one is a $39 access fee plus an entry dose. By month four, the access fee is running at whatever the chosen plan charges, the entry dose has usually stepped up at least twice, and any promotion tied to a low strength has ended. The same page that advertises the first figure contains all three of those facts. Building the month four number from it takes about five minutes and is the only version of the price that describes what treatment costs.
Frequently asked questions
Does the advertised membership price include the medication?
No. Ro states membership and medication as two separate charges and repeats on its insurance page that medication cost is not included in the membership fee. Someone on a prepaid membership taking a mid-range cash dose pays both lines every month, which is the arithmetic behind most surprise about totals.
Why does the medication price go up after a few months?
Because prices are published per dose and dosing escalates by design. Approved labeling sets out titration schedules for these agents, and the published price tables assign a different figure to each strength. A rise in the bill usually reflects a planned clinical step rather than a change in policy.
What does a sign-up deadline on an offer mean in practice?
It means the reduced price is available only to people who start before a stated date, and in the cases published on 24 July 2026, only at named strengths. Anyone starting later, or already past those strengths, pays the standard figure for that dose.
Is checking insurance worth the delay?
Often yes. A covered prescription is priced by a plan rather than by a platform, and a copay can sit well below any published cash figure. Self-pay terms in this category also commonly bar that spending from counting toward a deductible, which widens the gap beyond the sticker difference.
